Molecular Partners to Present at the Cowen And Company 39th Annual Healthcare Conference
Company to highlight the progress on its clinical DARPin®compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin®molecules targeting peptide MHC complexes supported by Gilead ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 11, 2019 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious...
Read more









